Travere Therapeutics, Inc.
TVTX
शेयरों में रैंक
#3497
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
शेयर मूल्य
$52.43
अंतिम समन्वयन: 2026-10-20
मार्केट कैप
$4.94B
बदलाव (1 दिन)
3.83%
बदलाव (1 वर्ष)
88.58%
देश
US
व्यापार Travere Therapeutics, Inc. (TVTX)
श्रेणी
Healthcare
Travere Therapeutics, Inc. (TVTX) के लिए कमाई
Jun 2026 में कमाई TTM: $-67.07M
Travere Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्टों के अनुसार, कंपनी की वर्तमान कमाई $-67.07M है। 2023 में कंपनी ने $-376.11M की कमाई की, जो 2022 की कमाई $-331.16M के की तुलना में कमी है। इस पृष्ठ पर दिखाई गई कमाई ब्याज और कर से पहले की कमाई है, जिसे EBIT कहा जाता है।
Travere Therapeutics, Inc. के लिए कमाई का इतिहास 2009 से 2026 तक
प्रत्येक वर्ष के अंत में कमाई
| वर्ष | कमाई | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $-67.07M | -79.07% |
| 2024 | $-320.51M | -14.78% |
| 2023 | $-376.11M | 13.58% |
| 2022 | $-331.16M | 52.69% |
| 2021 | $-216.88M | 14.88% |
| 2020 | $-188.79M | 28.91% |
| 2019 | $-146.45M | 43.76% |
| 2018 | $-101.87M | 74.54% |
| 2017 | $-58.36M | 1.36% |
| 2016 | $-57.58M | -154.60% |
| 2015 | $105.47M | -193.01% |
| 2014 | $-113.40M | 236.02% |
| 2013 | $-33.75M | 11.22% |
| 2012 | $-30.34M | 166,022.06% |
| 2009 | $-18.27K | 0.00% |
समान कंपनियों या प्रतियोगियों की कमाई
| कंपनी | कमाई | कमाई में अंतर | देश |
|---|---|---|---|
| $5.27B | -7,964.30% |
US
|
|
| $-3.09B | 4,502.38% |
US
|
|
| $-4.02B | 5,887.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,008.21% |
NL
|
